{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:23:19Z","timestamp":1786980199194,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus Kiel"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Combined immunotherapy (ipilimumab\u2009+\u2009nivolumab) has improved survival in stage IV melanoma patients, making Health-related Quality of Life (HrQoL) crucial due to potential immune-related adverse events (irAEs). Previous studies treated HrQoL as secondary\/explorative endpoint, and no specific HrQoL questionnaire for melanoma patients on immune checkpoint inhibitor (ICI) therapy exists. This study aimed to gather specific HrQoL data during combined ICI therapy, tracking changes during and after treatment, and examining associations with gender, irAEs, and treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>35 melanoma patients (22 males, 13 females) undergoing combined ICI were surveyed using the Short-form 36 questionnaire (SF-36), the Inflammatory Bowel Disease Questionnaire \u2013 Deutsch (IBDQ-D), and the distress thermometer (DT). HrQoL was evaluated during treatment, after six months, and at the onset of autoimmune colitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>irAEs occurred in 51.4% of patients, with colitis being the most common (26.1%). 45.7% had progressive disease. SF-36 showed stable HrQoL during treatment and follow-up. Women had worse HrQoL on the physical component scale than men (p\u2009=\u20090.019). Patients with progression showed worse HrQoL over time in physical (p\u2009=\u20090.015) and mental health scales (p\u2009=\u20090.04). IBDQ-D showed constant HrQoL throughout treatment and follow-up. Distress on DT remained constant, with women reporting higher levels of distress.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HrQoL remained stable during and after therapy. Female gender and disease progression negatively impacted HrQoL. The development of irAEs was not associated with HrQoL, though this may not apply to severe irAEs like colitis, which were not assessed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-024-05981-2","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T09:01:54Z","timestamp":1728550914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Quality of life under treatment with the immune checkpoint inhibitors ipilimumab and nivolumab in melanoma patients. Real-world data from a prospective observational study at the Skin Cancer Center Kiel"],"prefix":"10.1007","volume":"150","author":[{"given":"Carolin","family":"Grote","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Sophie","family":"Bohne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Blome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina C.","family":"K\u00e4hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"5981_CR1","doi-asserted-by":"crossref","first-page":"9029","DOI":"10.1200\/jco.2015.33.15_suppl.9029","volume":"33","author":"AP Abernethy","year":"2015","unstructured":"Abernethy AP, Postow MA, Chesney JA, Grossmann KF, Taylor F, Coon C, Gilloteau I, Dastani H, Gagnier P, Robert C (2015) Effect of nivolumab (NIVO) in combination with ipilimumab (IPI) versus IPI alone on quality of life (QoL) in patients (pts) with treatment-na\u00efve advanced melanoma (MEL): Results of a phase II study (CheckMate 069). J Clin Oncol 33:9029\u20139029","journal-title":"J Clin Oncol"},{"key":"5981_CR2","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/cncr.31943","volume":"125","author":"MH Antoni","year":"2019","unstructured":"Antoni MH, Dhabhar FS (2019) Impact of Psychosocial Stress and Stress Management on Immune Responses in Cancer Patients. Cancer 125:1417\u20131431","journal-title":"Cancer"},{"key":"5981_CR3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.hoc.2020.08.011","volume":"35","author":"NL Bolick","year":"2021","unstructured":"Bolick NL, Geller AC (2021) Epidemiology of Melanoma. Hematol Oncol Clin North Am 35:57\u201372","journal-title":"Hematol Oncol Clin North Am"},{"key":"5981_CR4","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejca.2021.10.005","volume":"159","author":"A Boutros","year":"1990","unstructured":"Boutros A, Bruzzone M, Tanda ET, Croce E, Arecco L, Cecchi F, Pronzato P, Ceppi M, Lambertini M (1990) Spagnolo F (2021): Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis. Eur J Cancer Oxf Engl 159:154\u2013166","journal-title":"Eur J Cancer Oxf Engl"},{"key":"5981_CR5","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino MS, Larkin J, Long GV (2021) Immune checkpoint inhibitors in melanoma. Lancet Lond Engl 398:1002\u20131014","journal-title":"Lancet Lond Engl"},{"issue":"3","key":"5981_CR6","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1002\/cam4.5183","volume":"12","author":"C Chen","year":"2023","unstructured":"Chen C, Wang Z, Qin YR (2023) Health-related quality of life in stage III-IV melanoma treated with targeted therapy or immunotherapy: A systematic review on the adequacy of reporting and clinical issues in phase III randomized controlled trials. Cancer Med 12(3):2262\u20132280","journal-title":"Cancer Med"},{"key":"5981_CR7","volume":"22","author":"F-E Cott\u00e9","year":"2020","unstructured":"Cott\u00e9 F-E, Voillot P, Bennett B, Falissard B, Tzourio C, Foulqui\u00e9 P, Gaudin A-F, Lemasson H, Grumberg V, McDonald L et al (2020) Exploring the health-related quality of life of patients treated with immune checkpoint inhibitors: Social Media Study. J Med Internet Res 22:e19694","journal-title":"J Med Internet Res"},{"key":"5981_CR8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejca.2021.08.026","volume":"157","author":"AM Da Silva Lopes","year":"1990","unstructured":"Da Silva Lopes AM, Colomer-Lahiguera S, Mederos Alfonso N, Aedo-Lopez V, Spurrier-Bernard G, Tolstrup LK, Pappot H, Aspeslagh S, Rogiers A, Neyns B et al (1990) (2021): Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study. Eur J Cancer Oxf Engl 157:225\u2013237","journal-title":"Eur J Cancer Oxf Engl"},{"key":"5981_CR9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","volume":"22","author":"EP Darnell","year":"2020","unstructured":"Darnell EP, Mooradian MJ, Baruch EN, Yilmaz M, Reynolds KL (2020) Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. Curr Oncol Rep 22:39","journal-title":"Curr Oncol Rep"},{"key":"5981_CR10","doi-asserted-by":"crossref","first-page":"9513","DOI":"10.1200\/JCO.2016.34.15_suppl.9513","volume":"34","author":"A Daud","year":"2016","unstructured":"Daud A, Blank CU, Robert C, Puzanov I, Richtig E, Margolin KA, O\u2019Day S, Nyakas M, Lutzky J, Tarhini AA et al (2016) KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy. J Clin Oncol 34:9513\u20139513","journal-title":"J Clin Oncol"},{"key":"5981_CR11","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.6004\/jnccn.2019.7358","volume":"17","author":"KA Donovan","year":"2019","unstructured":"Donovan KA, Deshields TL, Corbett C, Riba MB (2019) Update on the implementation of NCCN guidelines for distress management by NCCN member institutions. J Natl Compr Cancer Netw JNCCN 17:1251\u20131256","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"5981_CR12","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1007\/s11136-023-03427-9","volume":"32","author":"MD Egeler","year":"2023","unstructured":"Egeler MD, van de Poll-Franse LV, Tissier R, Rogiers A, Boers-Sonderen MJ, van den Eertwegh AJ, Hospers GA, de Groot JWB, Aarts MJB, Kapiteijn E et al (2023) Health-state utilities in long-term advanced melanoma survivors comparable with the general population. Qual Life Res 32:2517\u20132525","journal-title":"Qual Life Res"},{"key":"5981_CR13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113601","volume":"200","author":"M Egeler","year":"2024","unstructured":"Egeler M, Lai-Kwon J, Tissier R, Fraterman I, Kuijpers A, Van Houdt W, Wilgenhof S, Rao A, Sandhu S, Lee R, Eriksson H, van Leeuwen M, de Ligt K, van Akkooi A, van de Poll-Franse L (2024a) Real-world health-related quality of life outcomes for patients with resected stage III\/IV melanoma treated with adjuvant anti-PD1 therapy. Eur J Cancer 200:113601","journal-title":"Eur J Cancer"},{"key":"5981_CR14","doi-asserted-by":"crossref","first-page":"114176","DOI":"10.1016\/j.ejca.2024.114176","volume":"207","author":"MD Egeler","year":"2024","unstructured":"Egeler MD, van Leeuwen M, Lai-Kwon J, Eriksson H, Bartula I, Elashwah S, Fox L, Van Hemelrijck M et al (2024b) EORTC Quality of Life Group. Understanding quality of life issues in patients with advanced melanoma: Phase 1 and 2 in the development of the EORTC advanced melanoma module. Eur J Cancer Oxf Engl 207:114176","journal-title":"Eur J Cancer Oxf Engl"},{"key":"5981_CR15","unstructured":"Eigentler T, Hoge J, Garbe C, Schadendorf D (2020): Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge des Melanoms, Langversion 3.3, AWMF Registernummer: 032\/024OL, http:\/\/www.leitlinienprogramm- onkologie.de\/leitlinien\/melanom\/ (abgerufen am: 17.06.2024)"},{"key":"5981_CR16","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s00103-004-0933-1","volume":"47","author":"U Ellert","year":"2004","unstructured":"Ellert U, Kurth B-M (2004) Methodological views on the SF-36 summary scores based on the adult German population. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 47:1027\u20131032","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"5981_CR17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227344","volume":"15","author":"S Faury","year":"2020","unstructured":"Faury S, Foucaud J (2020) Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: A systematic review on reporting of methods in randomized controlled trials. PLoS ONE 15:e0227344","journal-title":"PLoS ONE"},{"key":"5981_CR18","doi-asserted-by":"crossref","first-page":"9514","DOI":"10.1200\/JCO.2017.35.15_suppl.9514","volume":"35","author":"A Forschner","year":"2017","unstructured":"Forschner A, Riedel P, Gassenmaier M, Scheu A, Kofler L, Garbe C, Sch\u00e4ffeler N, Mayer S, Eigentler TK (2017) The demand for psycho-oncological support in 820 melanoma patients: What are the determinants for the development of distress? J Clin Oncol 35:9514\u20139514","journal-title":"J Clin Oncol"},{"key":"5981_CR19","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejca.2022.03.008","volume":"170","author":"C Garbe","year":"2022","unstructured":"Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Del Marmol V, Dr\u00e9no B et al (2022) European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. Eur J Cancer Oxf Engl 170:236\u2013255","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"24","key":"5981_CR49","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.3390\/cells11243965","volume":"11","author":"A Guerrisi","year":"2022","unstructured":"Guerrisi A, Falcone I, Valenti F, Rao M, Gallo E, Ungania S, Maccallini MT, Fanciulli M, Frascione P, Morrone A, Caterino M (2022) Artificial intelligence and advanced melanoma: treatment management implications. Cells 11(24):3965. https:\/\/doi.org\/10.3390\/cells11243965","journal-title":"Cells"},{"key":"5981_CR20","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/cncr.32692","volume":"126","author":"AR Hansen","year":"2020","unstructured":"Hansen AR, Ala-Leppilampi K, McKillop C, Siu LL, Bedard PL, Abdul Razak AR, Spreafico A, Sridhar SS, Leighl N, Butler MO et al (2020) Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. Cancer 126:1550\u20131558","journal-title":"Cancer"},{"key":"5981_CR21","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R et al (2018) Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 19:1480\u20131492","journal-title":"Lancet Oncol"},{"key":"5981_CR22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/archdermatol.2010.433","volume":"147","author":"C Holterhues","year":"2011","unstructured":"Holterhues C, Cornish D, van de Poll-Franse LV, Krekels G, Koedijk F, Kuijpers D, Coebergh JW, Nijsten T (2011) Impact of melanoma on patients\u2019 lives among 562 survivors: a Dutch population-based study. Arch Dermatol 147:177\u2013185","journal-title":"Arch Dermatol"},{"key":"5981_CR23","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2023.151574","volume":"40","author":"N Jackson-Carroll","year":"2024","unstructured":"Jackson-Carroll N, Johnson C, Tawbi H, Wang XS, Whisenant M (2024) The symptom experience of patients with advanced melanoma undergoing immune checkpoint inhibitor (ICI) therapy. Semin Oncol Nurs 40:151574","journal-title":"Semin Oncol Nurs"},{"key":"5981_CR24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1055\/s-2006-932661","volume":"56","author":"K-H Janke","year":"2006","unstructured":"Janke K-H, Klump B, Steder-Neukamm U, Hoffmann J, H\u00e4user W (2006) Validation of the German version of the Inflammatory Bowel Disease Questionnaire (Competence Network IBD, IBDQ-D). Psychother Psychosom Med Psychol 56:291\u2013298","journal-title":"Psychother Psychosom Med Psychol"},{"key":"5981_CR25","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1001\/archdermatol.2009.308","volume":"145","author":"NA Kasparian","year":"2009","unstructured":"Kasparian NA, McLoone JK, Butow PN (2009) Psychological responses and coping strategies among patients with malignant melanoma: a systematic review of the literature. Arch Dermatol 145:1415\u20131427","journal-title":"Arch Dermatol"},{"key":"5981_CR26","volume":"100","author":"B Kim","year":"2021","unstructured":"Kim B, Chae J, Kim EH, Yang HI, Cheon JH, Kim TI, Kim WH, Jeon JY, Park SJ (2021) Physical activity and quality of life of patients with inflammatory bowel disease. Medicine (Baltimore) 100:e26290","journal-title":"Medicine (Baltimore)"},{"key":"5981_CR27","doi-asserted-by":"crossref","DOI":"10.2196\/30042","volume":"23","author":"A Knapp","year":"2021","unstructured":"Knapp A, Harst L, Hager S, Schmitt J, Scheibe M (2021) Use of patient-reported outcome measures and patient-reported experience measures within evaluation studies of telemedicine applications: systematic review. J Med Internet Res 23:e30042","journal-title":"J Med Internet Res"},{"issue":"1","key":"5981_CR28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/bjd\/ljae011","volume":"191","author":"G Kungwengwe","year":"2024","unstructured":"Kungwengwe G, Gowthorpe C, Ali SR, Warren H, Drury DJ, Ang KL, Gibson JAG, Dobbs TD, Whitaker IS (2024) Prevalence and odds of anxiety and depression in cutaneous malignant melanoma: a proportional meta-analysis and regression. Br J Dermatol 191(1):24\u201335","journal-title":"Br J Dermatol"},{"key":"5981_CR29","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/annonc\/mdw265","volume":"27","author":"GV Long","year":"2016","unstructured":"Long GV, Atkinson V, Ascierto PA, Robert C, Hassel JC, Rutkowski P, Savage KJ, Taylor F, Coon C, Gilloteau I et al (2016) Effect of nivolumab on health-related quality of life in patients with treatment-na\u00efve advanced melanoma: results from the phase III CheckMate 066 study. Ann Oncol off J Eur Soc Med Oncol 27:1940\u20131946","journal-title":"Ann Oncol off J Eur Soc Med Oncol"},{"key":"5981_CR30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066800","volume":"8","author":"C Loquai","year":"2013","unstructured":"Loquai C, Scheurich V, Syring N, Schmidtmann I, Rietz S, Werner A, Grabbe S, Beutel ME (2013) Screening for distress in routine oncological care-a survey in 520 melanoma patients. PLoS ONE 8:e66800","journal-title":"PLoS ONE"},{"key":"5981_CR31","first-page":"1","volume":"170","author":"A Machingura","year":"1990","unstructured":"Machingura A, Taye M, Musoro J, Ringash J, Pe M, Coens C, Martinelli F, Tu D, Basch E, Brandberg Y et al (1990) (2022): Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: Validation study. Eur J Cancer Oxf Engl 170:1\u20139","journal-title":"Eur J Cancer Oxf Engl"},{"key":"5981_CR32","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1055\/s-2006-951828","volume":"56","author":"A Mehnert","year":"2006","unstructured":"Mehnert A, Lehmann C, Cao P, Koch U (2006) Assessment of psychosocial distress and resources in oncology\u2013a literature review about screening measures and current developments. Psychother Psychosom Med Psychol 56:462\u2013479","journal-title":"Psychother Psychosom Med Psychol"},{"key":"5981_CR33","doi-asserted-by":"crossref","unstructured":"Merrick S, Rush HL, Daniels S, Fielding A, Deveson Kell S, Pickering L, Langley RE, South A, Gilbert DC (2024): Hit it hard: qualitative patient perspectives on the optimisation of immune checkpoint inhibition. Br J Cancer","DOI":"10.1038\/s41416-024-02756-x"},{"key":"5981_CR34","unstructured":"Morfeld M, Kirchberger I, Bullinger M (2011) SF-36 Fragebogen zum Gesundheitszustand. Deutsche Version des Short Form-36 Health Survey 2., erg\u00e4nzte und \u00fcberarbeitete Auflage; Hogrefe Verlag GmbH&Co."},{"key":"5981_CR35","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00520-019-04818-w","volume":"28","author":"A O\u2019Reilly","year":"2020","unstructured":"O\u2019Reilly A, Hughes P, Mann J, Lai Z, Teh JJ, Mclean E, Edmonds K, Lingard K, Chauhan D, Lynch J et al (2020) An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors. Support Care Cancer 28:561\u2013570","journal-title":"Support Care Cancer"},{"key":"5981_CR36","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/0284186X.2023.2165449","volume":"62","author":"S Pedersen","year":"2023","unstructured":"Pedersen S, Holmstroem RB, von Heymann A, Tolstrup LK, Madsen K, Petersen MA, Haslund CA, Ruhlmann CH, Schmidt H, Johansen C et al (2023) Quality of life and mental health in real-world patients with resected stage III\/IV melanoma receiving adjuvant immunotherapy. Acta Oncol Stockh Swed 62:62\u201369","journal-title":"Acta Oncol Stockh Swed"},{"key":"5981_CR37","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s001030050033","volume":"43","author":"M Radoschewski","year":"2000","unstructured":"Radoschewski M (2000) Gesundheitsbezogene Lebensqualit\u00e4t \u2013 Konzepte und Ma\u00dfe. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 43:165\u2013189","journal-title":"Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"},{"key":"5981_CR38","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00403-022-02479-0","volume":"315","author":"ME Reinhardt","year":"2023","unstructured":"Reinhardt ME, Sun T, Pan CX, Schmults CD, Lee EH, Waldman AB (2023) A systematic review of patient-reported outcome measures for advanced skin cancer patients. Arch Dermatol Res 315:1473\u20131480","journal-title":"Arch Dermatol Res"},{"key":"5981_CR39","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1200\/JCO.22.01599","volume":"41","author":"C Robert","year":"2023","unstructured":"Robert C, Carlino MS, McNeil C, Ribas A, Grob J-J, Schachter J, Nyakas M, Kee D, Petrella TM, Blaustein A et al (2023) Seven-year follow-up of the phase III KEYNOTE-006 Study: Pembrolizumab versus ipilimumab in advanced melanoma. J Clin Oncol off J Am Soc Clin Oncol 41:3998\u20134003","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"key":"5981_CR40","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejca.2017.05.031","volume":"82","author":"D Schadendorf","year":"1990","unstructured":"Schadendorf D, Larkin J, Wolchok J, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J-J, Cowey CL, Lao C et al (1990) (2017): Health-related quality of life results from the phase III CheckMate 067 study. Eur J Cancer Oxf Engl 82:80\u201391","journal-title":"Eur J Cancer Oxf Engl"},{"key":"5981_CR41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2022.08.029","volume":"176","author":"TU Schulz","year":"1990","unstructured":"Schulz TU, Zierold S, Sachse MM, Pesch G, Tomsitz D, Schilbach K, K\u00e4hler KC, French LE, Heinzerling L (2022) Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients\u2019 health-related quality of life. Eur J Cancer Oxf Engl 176:88\u201399","journal-title":"Eur J Cancer Oxf Engl"},{"key":"5981_CR42","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J et al (2016) RECIST 1.1 \u2013 update and clarification: from the RECIST Committee. Eur J Cancer Oxf Engl 62:132\u2013137","journal-title":"Eur J Cancer Oxf Engl"},{"key":"5981_CR43","doi-asserted-by":"crossref","first-page":"405","DOI":"10.12998\/wjcc.v7.i4.405","volume":"7","author":"A Som","year":"2019","unstructured":"Som A, Mandaliya R, Alsaadi D, Farshidpour M, Charabaty A, Malhotra N, Mattar MC (2019) Immune checkpoint inhibitor-induced colitis: A comprehensive review. World J Clin Cases 7:405\u2013418","journal-title":"World J Clin Cases"},{"key":"5981_CR44","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/bjd.16098","volume":"178","author":"AD Tran","year":"2018","unstructured":"Tran AD, Fogarty G, Nowak AK, Espinoza D, Rowbotham N, Stockler MR, Morton RL (2018) A systematic review and meta-analysis of utility estimates in melanoma. Br J Dermatol 178:384\u2013393","journal-title":"Br J Dermatol"},{"key":"5981_CR45","volume":"13","author":"PC Vinke","year":"2023","unstructured":"Vinke PC, Combalia M, de Bock GH, Leyrat C, Spanjaart AM, Dalle S, Gomes da Silva M, Fouda Essongue A, Rabier A, Pannard M et al (2023) Monitoring multidimensional aspects of quality of life after cancer immunotherapy: protocol for the international multicentre, observational QUALITOP cohort study. BMJ Open 13:e069090","journal-title":"BMJ Open"},{"key":"5981_CR46","first-page":"1761","volume":"26","author":"RI Vogel","year":"2017","unstructured":"Vogel RI, Strayer LG, Engelman L, Nelson HH, Blaes AH, Anderson KE, Lazovich D (2017) Comparison of quality of life among long-term melanoma survivors and non-melanoma controls: a cross-sectional study. Qual Life Res Int J Qual Life Asp Treat Care Rehabil 26:1761\u20131766","journal-title":"Qual Life Res Int J Qual Life Asp Treat Care Rehabil"},{"key":"5981_CR47","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1007\/s00520-021-06046-7","volume":"29","author":"RI Vogel","year":"2021","unstructured":"Vogel RI, Yoerg B, Jewett PI, Rubin N, Olson M, Stenzel AE, Ahmed RL, Lazovich D (2021) Cross-sectional study of sex differences in psychosocial quality of life of long-term melanoma survivors. Support Care Cancer off J Multinatl Assoc 29:5663\u20135671","journal-title":"Support Care Cancer off J Multinatl Assoc"},{"key":"5981_CR48","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.3390\/cancers13112642","volume":"13","author":"L Wiens","year":"2021","unstructured":"Wiens L, Sch\u00e4ffeler N, Eigentler T, Garbe C, Forschner A (2021) Psychological distress of metastatic melanoma patients during treatment with immune checkpoint inhibitors: results of a prospective study. Cancers 13:2642","journal-title":"Cancers"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05981-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05981-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05981-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T08:05:04Z","timestamp":1730793904000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05981-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":49,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["5981"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05981-2","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]},"assertion":[{"value":"30 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Carolin Grote received travel grants from Almirall and Celltrion and speaker fees from BMS and MSD; Ann-Sophie Bohne has received travel grants from Sun Pharma, Pierre-Fabre, BMS and Mallinckrodt Pharmaceuticals; Christine Blome has received speaker honoraria, research grants and\/or awards from Amgen\/Celgene, AstraZeneca, Bauerfeind, Deutsche Gesellschaft f\u00fcr ME\/CFS, Hartmann, Helios Klinik Leisnig, Janssen-Cilag, Kreussler, Lilly, Mapi Group, medi, Pfizer, Stiefel Laboratories, The EuroQol Group, UCB, and Urgo; Katharina K\u00e4hler serves as consultant to Philogen, BMS, MSD, Sanofi Aventis, Immunocore and received travel grants and speaker fees from Philogen, Pierre Fabre, BMS, MSD, Sun Pharma, Sanofi Aventis, Novartis, Medac and has received research support by Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"454"}}